Biopolym. Cell. 2020; 36(4):304-312.
Biomedicine
Personalized responsiveness of human PBMCs to the action of IL-7
1Kovalchuk M. V., 1Ruban T. A., 1Usenko M. O., 1Kordium V. A.
  1. Institute of Molecular Biology and Genetics, NAS of Ukraine
    150, Akademika Zabolotnoho Str., Kyiv, Ukraine, 03143

Abstract

Interleukin-7 (IL-7) is an important element in the functioning of the immune system. Therefore, it would be appropriate to assess individual responses of the immune cells to IL-7. Aim. To analyze ex vivo responses of the healthy adult individual T cells to increasing rhIL-7 concentrations. Methods. Isolation and cultivation of PBMCs and in vitro cytokine bioassay. Quantitative determination of cell viability was performed by the metabolic MTT-uptake assay in viable cells. EC50 was calculated by means of OriginPro7,5. Results. The dose-response effect on T cell subsets of PBMCs for different concentrations of rhIL-7 in individuals in vitro was evaluated. [The] IL-7 bioassay revealed that the individual EC50 values ranged from 0.41 to 1.5 ng/ml. Inter-individual variability was high for EC50 values (CVG=38 %). Maximal percentage increase in cell viability among subjects demonstrated moderate variability (CVG=15 %). Conclusions. The study revealed that responsiveness to IL-7 is various for the PBMCs originated from different individuals. Our research assumes that the personalized responsiveness of human PBMCs to IL-7 may be considered as valuable prognostic information about the immune system state and the T cells response to IL-7-based therapies. The advantage of the optimized bioassay for the detection sensitivity of PBMC response to IL-7 was shown.
Keywords: IL-7, PBMCs, inter-individual variability.

References

[1] Namen AE, Lupton S, Hjerrild K, Wignall J, Mochizuki DY, Schmierer A, Mosley B, March CJ, Urdal D, Gillis S. Stimulation of B-cell progenitors by cloned murine interleukin-7. Nature. 1988; 333:571-3.
[2] Churchman SM, El-Jawhari JJ, Burska AN, Parmar R, Goëb V, Conaghan PG, Emery P, Ponchel F. Modulation of peripheral T-cell function by interleukin-7 in rheumatoid arthritis. Arthritis Res Ther. 2014; 16(6):511-24.
[3] Kondrack RM, Harbertson J, Tan JT, McBreen ME, Surh CD, Bradley LM. Interleukin 7 Regulates the Survival and Generation of Memory CD4 Cells. J Exp Med. 2003; 198(12):1797-806.
[4] A Reum Kim, Junsik Park, Jong Hoon Kim, Jeong-Eun Kwak, Youngran Cho, Hyojin Lee, Moonsup Jeong, Su-Hyung Park, Eui-Cheol Shin. Herpes Zoster DNA Vaccines with IL-7 and IL-33 Molecular Adjuvants Elicit Protective T Cell Immunity. Immune Netw. 2018. 18(5): e38.
[5] Nam HJ. Song MY, Choi DH, Yang SH, Jin HT, Sung YC. Marked enhancement of antigen-specific T-cell responses by IL-7-fused nonlytic, but not lytic, Fc as a genetic adjuvant. Eur J Immunol. 2010; 40(2):351-8.
[6] Gao J, Zhao L, Wan YY, Zhu B. Mechanism of Action of L-7 and Its Potential Applications and Limitations in Cancer Immunotherapy. Int J Mol Sci. 2015; 16(5):10267-80.
[7] Mazzucchelli R, Durum SK. Interleukin-7 receptor expression: intelligent design. Nat Rev Immunol. 2007; 7(2):144-54.
[8] Vudattu NK, Kuhlmann-Berenzon S, Khademi M, Seyfert V, Olsson T, Maeurer MJ. Increased Numbers of IL-7 Receptor Molecules on CD4+CD25−CD107a+ T-Cells in Patients with Autoimmune Diseases Affecting the Central Nervous System. PLoS ONE. 2009; 4(8):e6534.
[9] Hengires CM, Rino J, Nibbs RJ, Graham GJ, Barata JT. IL-7 induces rapid clathrin-mediated internalization and JAK3-dependent degradation of IL-7Rα in T cells. Blood. 2010; 115(16):3269-77.
[10] Faller EM, Ghazawi FM, Cavar M, MacPherson PA. IL-7 induces clathrin mediated endocytosis of CD127 and subsequent degradation by the proteasome in primary human CD8 T cells. Immunol Cell Biol. 2016; 94(2):196-207.
[11] Kang J, Coles M. IL-7: the global builder of the innate lymphoid network and beyond, one niche at a time. Semin Immunol. 2012; 24(3):190-7.
[12] Van de Loosdrecht AA, Beelen RH, Ossenkoppele GJ, Broekhoven MG, Langenhuijsen MM. A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukaemia. J Immunol Methods. 1994; 174(1-2):311-20.
[13] Griffin JF, Bulmer R, Wilson EW. Cord blood lymphocyte subpopulations and mitogenic activity in whole blood microculture. J Reprod Immunol. 1979; 1(4):219-27.
[14] Burska A, Boissinot M, Ponchel F. Cytokines as biomarkers in rheumatoid arthritis. Mediators Inflamm. 2014;2014:545493
[15] Sathaliyawala T, Kubota M, Yudanin N, Turner D, Camp P, Thome JC, Bickham KL, Lerner H, Goldstein M, Sykes M, Kato T, Farber DL. Distribution and compartmentalization of human circulating and tissue-resident memory T cell subsets. Immunity. 2013; 38(1):187-97.
[16] Hassan J, Reen DJ. Human Recent Thymic Emigrants-Identification, Expansion, And Survival Characteristics. J Immunol. 2001; 167(4): 1970-6.
[17] Cote S, Matte J, Sad S, Angel JB, Crawley AM. Complexed soluble IL-7 receptor α and IL-7 increase IL-7-mediated proliferation and viability of CD8+ T-cells in vitro. Cell Immunol 2015; 293(2):122-5.
[18] Akbar AN, Salmon M. Cellular environments and apoptosis: tissue microenvironments control activated T-cell death. Immunol Today. 1997; 18(2):72-6.
[19] Bortwick NJ, Lowdell M, Salmon M, Akbar AN. Loss of CD28 expression on CD8+ T cells is induced by IL-2 receptor γ chain signalling cytokines and type I IFN, and increases susceptibility to activation-induced apoptosis. Int Immunol. 2000; 12(7):1005-13.
[20] Brodin P, Davis MM. Human immune system variation. Nat Rev Immunol. 2017;17(1):21-9.
[21] Aziz N, Detels R, Quint JJ, Gjertson D, Ryner T, Butch AW. Biological variation of immunological blood biomarkers in healthy individuals and quality goals for biomarker tests. BMC Immunology. 2019; 20(1):33